Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

20201,241 citationsJournal Articlebronze Open Access

Authors

Kohei Shitara · National Cancer Center Hospital East

Yung‐Jue Bang · New Generation University College

Satoru Iwasa · National Cancer Center

Naotoshi Sugimoto · Osaka Medical Center for Cancer and Cardiovascular Diseases

Min‐Hee Ryu · University of Ulsan

Daisuke Sakai · Osaka University Hospital

Hyun Cheol Chung

Abstract

Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number, NCT03329690.).

Topics & Keywords

Gastric Cancer Management and Outcomes HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 25, pp. 2419-2430

DOI: 10.1056/nejmoa2004413

Field-Weighted Citation Impact: 87.72